San Francisco, June 06, 2025 - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, has announced the approval of non-qualified stock options for three new employees. This decision, made by the Compensation Committee of the Company's Board of Directors, involves the issuance of options to purchase a total of 61,100 shares of 89bio's common stock. These inducement grants, effective June 3, 2025, are part of the 2023 Inducement Plan and align with Nasdaq Listing Rule 5635(c)(4). The exercise price for these options corresponds to the closing price on the grant date, and the options will vest over four years, with 25% vesting at the end of the first year and the remainder vesting quarterly, contingent upon continued employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.